key: cord-0956170-v297yyh1
authors: Jindal, Anuradha; Ramesh, Sandhiya; Noronha, Malcom; Pai, Kantilatha; Pai, Sathish
title: Intramatricial methotrexate for treatment of resistant acrodermatitis continua of Hallopeau: an alterative in Covid‐19
date: 2020-06-08
journal: Dermatol Ther
DOI: 10.1111/dth.13787
sha: 18cdff2aa99bfd6063a727fa7975521bde0158d8
doc_id: 956170
cord_uid: v297yyh1

nan

Methotrexate is a folic acid analog with anti-inflammatory, anti-proliferative and immunosuppressive effect. The mechanism of actions of methotrexate can be divided into DHR (dihydrofolate reductase) mediated and non-DHR mediated. 3 Methotrexate also promotes apoptosis of activated CD4 T cells and reduces neovascularization. 4 Intralesional methotrexate has been tried for the treatment of keratoacanthoma, 5 CD30+ lymphoma, 6 nail psoriasis, 7 resistant case of pyoderma gangrenosum 8 in the past. MG Yoo and IH kim reported 11 cases of keratoacanthoma who were treated with 0.1 to 0.8 ml 12.5-25mg/ml of methotrexate intralesional at an interval of average 10 days with significant reduction in size of lesions with an average of 4.3 sessions per patient. 9 Review of literature shows the use of low dose intralesional methotrexate is a relatively safe procedure and is not associated with any significant adverse effects. This is the first case illustrating the use of This article is protected by copyright. All rights reserved.

intralesional methotrexate for acrodermatitis continua of Hallopeau. As the Severe acute respiratory syndrome coronavirus-2 (SARS-CoV2) has captivated more than more than 4.9 million people across the globe with more than 40-60% patients being asymptomatic, treating recalcitrant cases of ACH intramatricial methotrexate migth be a considerable alterative bypassing the systemic adverse effects of immunosupression while providing optimum results.

This article is protected by copyright. All rights reserved. 

Novel Coronavirus Disease (COVID-19) and Biologic Therapy in Psoriasis: Infection Risk and Patient Counseling in Uncertain Times

Efficacy of methotrexate as anti-inflammatory and anti-proliferative drug in dermatology: Three cases

Methotrexate and psoriasis in the era of new biologic agents

Intralesional therapy for the treatment of keratoacanthoma

Treatment of primary cutaneous CD30+ anaplastic large cell lymphoma with intralesional methotrexate

Intramatricial injections for nail psoriasis: An open-label comparative study of triamcinolone, methotrexate, and cyclosporine